Detalles de la búsqueda
1.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Mol Cancer;
23(1): 61, 2024 03 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519913
2.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Lancet Oncol;
24(8): 925-935, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37541273
3.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Lancet Oncol;
24(8): 892-902, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429302
4.
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
Am J Hematol;
98(4): 645-657, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36606708
5.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet;
398(10295): 131-142, 2021 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34246347
6.
Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study.
Support Care Cancer;
30(12): 9841-9849, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36271944
7.
Late phase 1 studies: concepts and outcomes.
Lancet Oncol;
22(10): e446-e455, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34592194
8.
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Cancer;
127(10): 1620-1629, 2021 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33496357
9.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Cancer Immunol Immunother;
70(1): 221-232, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700090
10.
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Invest New Drugs;
39(1): 193-201, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32915419
11.
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Invest New Drugs;
39(4): 1089-1098, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686452
12.
Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Oncologist;
25(5): 369-374, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32091646
13.
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Invest New Drugs;
38(2): 402-409, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30953269
14.
Pembrolizumab monotherapy for advanced chordoma - Authors' reply.
Lancet Oncol;
24(10): e400, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37797638
15.
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Lancet Oncol;
19(9): 1180-1191, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30120041
16.
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?
Br J Cancer;
119(8): 937-939, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30327567
17.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.
Invest New Drugs;
36(4): 619-628, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29094232
18.
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Invest New Drugs;
36(1): 62-74, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28597151
19.
The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.
Genet Med;
19(6): 683-690, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27906201
20.
Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.
Invest New Drugs;
35(1): 79-86, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27783256